Sanofi Prices $3 Billion Bond Issue
Sanofi has made a significant announcement regarding its bond issue, successfully pricing a substantial offering of $3 billion across five distinct tranches. This is a pivotal move for the company as it continues to navigate its growth strategies in the ever-evolving biopharmaceutical landscape.
Details of the Offering
This comprehensive bond issue consists of several critical components aimed at attracting investors who seek reliable returns. The offerings include:
- $400 million in fixed-rate notes maturing in November 2027, with an interest rate of 3.75%.
- $500 million in floating-rate notes due in November 2027, tied to compounded SOFR plus 0.46%.
- $400 million in fixed-rate notes maturing in November 2028, offering an interest rate of 3.80%.
- $500 million in floating-rate notes due in November 2028, linked to compounded SOFR plus 0.54%.
- $1.2 billion in fixed-rate notes maturing in November 2032, featuring a higher interest rate of 4.20%.
Utilization of Proceeds
Sanofi plans to direct the net proceeds from this bond offering toward general corporate purposes. This strategic decision allows the company to enhance its operational capabilities and further invest in innovative solutions within the biopharmaceutical sector.
Strategic Underwriters
A competent team of financial institutions has come together to facilitate this bond issue. Barclays Capital Inc., BNP Paribas Securities Corp., and BofA Securities, Inc. served as Global Coordinators, while several other reputable firms acted as Joint Book-Running Managers. Their expertise will ensure an efficient and successful transaction.
About Sanofi
Sanofi stands at the forefront of the pharmaceutical industry, driven by research and development and empowered by artificial intelligence. The company is dedicated to enhancing the lives of individuals around the globe through the innovative creation of medicines and vaccines that address numerous health challenges. The company's ambitious pipeline continues to hold the promise of future advancements that could significantly benefit millions more.
Every day, Sanofi’s dedicated professionals work tirelessly in pursuit of scientific breakthroughs. They are motivated by a fundamental mission: to leverage the miracles of science to improve lives, while committing to positive social impact and addressing pressing healthcare and societal challenges.
Sanofi is publicly traded and listed on EURONEXT: SAN and NASDAQ: SNY.
Contact for Media Relations
Sandrine Guendoul
+ 33 6 25 09 14 25
sandrine.guendoul@sanofi.com
Evan Berland
+1 215 432 0234
evan.berland@sanofi.com
Victor Rouault
+ 33 6 70 93 71 40
victor.rouault@sanofi.com
Léo Le Bourhis
+ 33 6 75 06 43 81
leo.lebourhis@sanofi.com
Frequently Asked Questions
What is the total amount raised by Sanofi's bond issue?
Sanofi successfully raised a total of $3 billion through its bond offering.
What are the key features of the bond offerings?
The bond issue comprises fixed and floating rate notes with varying maturity dates, ranging from 2027 to 2032.
Who were the key underwriters for this bond issue?
Barclays Capital, BNP Paribas Securities, and BofA Securities acted as Global Coordinators, along with other firms serving as Joint Book-Running Managers.
How will Sanofi utilize the proceeds from the bond issue?
The net proceeds will be used primarily for general corporate purposes, enhancing Sanofi's operational capabilities.
What is Sanofi's mission in the pharmaceutical industry?
Sanofi is dedicated to improving lives through innovative medicines and vaccines, focusing on significant healthcare challenges.
